Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized trial of cisplatin-radiotherapy versus durvalumab-radiotherapy in intermediate-risk HPV-positive locally advanced oropharyngeal cancer
2019-000308-13Phase 2Active
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Jun 2019
- Modality
- Small Molecules, PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of durvalumab, cisplatin and tremelimumab in oropharyngeal squamous cell carcinoma (OPSCC) (3 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Event-free survival. Started Jun 2019; status: active.
02
Drugs
durvalumabcisplatintremelimumab
03
Conditions
oropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on 2019-000308-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000308-13.